Role of late sodium current in modulating the proarrhythmic and antiarrhythmic effects of quinidine.
暂无分享,去创建一个
Lin Wu | Charles Antzelevitch | C. Antzelevitch | Donglin Guo | J. Shryock | L. Belardinelli | G. Yan | Lin Wu | Hong Li | Luiz Belardinelli | Gan-Xin Yan | Zhen Jiao | Hong Li | Donglin Guo | John C Shryock | James Hackett | J. Hackett | Zhen Jiao | James Hackett
[1] D. Roden,et al. Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. , 1986, American heart journal.
[2] H. Mabuchi,et al. T wave peak-to-end interval and QT dispersion in acquired long QT syndrome: a new index for arrhythmogenicity. , 2003, Clinical science.
[3] E. Aliot,et al. The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis. , 1988, Progress in cardiovascular diseases.
[4] J. Reiffel. Inpatient versus outpatient antiarrhythmic drug initiation: safety and cost-effectiveness issues. , 2000, Current opinion in cardiology.
[5] J. Shryock,et al. An Increase in Late Sodium Current Potentiates the Proarrhythmic Activities of Low-Risk QT-Prolonging Drugs in Female Rabbit Hearts , 2006, Journal of Pharmacology and Experimental Therapeutics.
[6] P. Kowey,et al. Regression of left ventricular hypertrophy with captopril restores normal ventricular action potential duration, dispersion of refractoriness, and vulnerability to inducible ventricular fibrillation. , 1997, Circulation.
[7] F. Cappuccio,et al. Risk of Cardiac Arrhythmia Variant of SCN 5 A Sodium Channel Implicated in , 2007 .
[8] E. Kaufman. Quinidine in Short QT Syndrome: An Old Drug for a New Disease , 2007, Journal of cardiovascular electrophysiology.
[9] Milan Stengl,et al. Increased Short-Term Variability of Repolarization Predicts d-Sotalol–Induced Torsades de Pointes in Dogs , 2004, Circulation.
[10] G. Breithardt,et al. Reduction of Dispersion of Repolarization and Prolongation of Postrepolarization Refractoriness Explain the Antiarrhythmic Effects of Quinidine in a Model of Short QT Syndrome , 2007, Journal of cardiovascular electrophysiology.
[11] N. Benowitz,et al. Poisoning Due to Class IA Antiarrhythmic Drugs , 1990 .
[12] Antoine Leenhardt,et al. Hydroquinidine therapy in Brugada syndrome. , 2004, Journal of the American College of Cardiology.
[13] J. Ruskin,et al. Augmentation of late sodium current unmasks the proarrhythmic effects of amiodarone. , 2008, Cardiovascular research.
[14] L. Toivonen,et al. Further evidence of inherited long QT syndrome gene mutations in antiarrhythmic drug-associated torsades de pointes. , 2007, Heart rhythm.
[15] J. Salata,et al. Effects of Quinidine on Action Potentials and Ionic Currents in Isolated Canine Ventricular Myocytes , 1988, Circulation research.
[16] J. M. Di Diego,et al. Cisapride-Induced Transmural Dispersion of Repolarization and Torsade de Pointes in the Canine Left Ventricular Wedge Preparation During Epicardial Stimulation , 2003, Circulation.
[17] M. Pepe. The Statistical Evaluation of Medical Tests for Classification and Prediction , 2003 .
[18] J. Shryock,et al. Use of preclinical assays to predict risk of drug-induced torsades de pointes. , 2005, Heart rhythm.
[19] M. Sokolow. Some quantitative aspects of treatment with quinidine. , 1956, Annals of internal medicine.
[20] J. Papp,et al. Comparison of the Effect of Class IA Antiarrhythmic Drugs on Transmembrane Potassium Currents in Rabbit Ventricular Myocytes , 2003, Journal of cardiovascular pharmacology and therapeutics.
[21] P. C. Viswanathan,et al. Allelic Variants in Long-QT Disease Genes in Patients With Drug-Associated Torsades de Pointes , 2002, Circulation.
[22] H. Tan,et al. Electrophysiologic Mechanisms of the Long QT Interval Syndromes and Torsade de Pointes , 1995, Annals of Internal Medicine.
[23] G. Naccarelli,et al. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials. , 2003, The American journal of cardiology.
[24] D. Roden,et al. Extracellular potassium modulation of drug block of IKr. Implications for torsade de pointes and reverse use-dependence. , 1996, Circulation.
[25] R. Lazzara. Antiarrhythmic drugs and torsade de pointes. , 1993, European heart journal.
[26] N. Benowitz,et al. Poisoning due to class IA antiarrhythmic drugs. Quinidine, procainamide and disopyramide. , 1990, Drug safety.
[27] Charles Antzelevitch,et al. Cellular basis for arrhythmogenesis in an experimental model of the SQT1 form of the short QT syndrome. , 2008, Heart rhythm.
[28] M. Cárdenas,et al. Ionic Basis of Pharmacological Therapy in Brugada Syndrome , 2007, Journal of cardiovascular electrophysiology.
[29] S. Swiryn,et al. Torsade de pointes due to quinidine: observations in 31 patients. , 1984, American heart journal.